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Polyfunctional, Proinflammatory, Tissue- Resident Memory 
Phenotype and Function of Synovial Interleukin- 17A+CD8+ 
T Cells in Psoriatic Arthritis
Kathryn J. A. Steel,1 Ushani Srenathan,1 Michael Ridley,1 Lucy E. Durham,1 Shih-Ying Wu,1 Sarah E. Ryan,1 
Catherine D. Hughes,2 Estee Chan,3 Bruce W. Kirkham,3 and Leonie S. Taams1
Objective. Genetic associations imply a role for CD8+ T cells and the interleukin- 23 (IL- 23)/IL- 17 axis in psoriatic 
arthritis (PsA) and other spondyloarthritides (SpA). IL- 17A+CD8+ (Tc17) T cells are enriched in the synovial fluid (SF) of 
patients with PsA, and IL- 17A blockade is clinically efficacious in PsA/SpA. This study was undertaken to determine 
the immunophenotype, molecular profile, and function of synovial Tc17 cells in order to elucidate their role in PsA/SpA 
pathogenesis.
Methods. Peripheral blood (PB) and SF mononuclear cells were isolated from patients with PsA or other types 
of SpA. Cells were phenotypically, transcriptionally, and functionally analyzed by flow cytometry (n = 6–18), T cell 
receptor β (TCRβ) sequencing (n = 3), RNA- Seq (n = 3), quantitative reverse transcriptase–polymerase chain reaction 
(n = 4), and Luminex or enzyme- linked immunosorbent assay (n = 4–16).
Results. IL- 17A+CD8+ T cells were predominantly TCRαβ+ and their frequencies were increased in the SF versus 
the PB of patients with established PsA (P < 0.0001) or other SpA (P = 0.0009). TCRβ sequencing showed that these 
cells were polyclonal in PsA (median clonality 0.08), while RNA- Seq and deep immunophenotyping revealed that PsA 
synovial Tc17 cells had hallmarks of Th17 cells (RORC/IL23R/CCR6/CD161) and Tc1 cells (granzyme A/B). Synovial 
Tc17 cells showed a strong tissue- resident memory T (Trm) cell signature and secreted a range of proinflammatory 
cytokines. We identified CXCR6 as a marker for synovial Tc17 cells, and increased levels of CXCR6 ligand CXCL16 
in PsA SF (P = 0.0005), which may contribute to their retention in the joint.
Conclusion. Our results identify synovial Tc17 cells as a polyclonal subset of Trm cells characterized by polyfunc-
tional, proinflammatory mediator production and CXCR6 expression. The molecular signature and functional profiling 
of these cells may help explain how Tc17 cells can contribute to synovial inflammation and disease persistence in 
PsA and possibly other types of SpA.
INTRODUCTION
Psoriatic arthritis (PsA) is part of an umbrella group of inflam-
matory diseases, termed spondyloarthritides (SpA), that share 
common patterns of joint inflammation (peripheral and axial); 
skin, gut, and eye manifestations; genetic components; and the 
absence of diagnostic autoantibodies (seronegativity). In addition 
to PsA, SpA includes ankylosing spondylitis (AS)/nonradiographic 
axial spondylitis, reactive arthritis, enteropathic arthritis, and undif-
ferentiated SpA, with a combined prevalence of 1–2% (1).
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It is increasingly recognized that the interleukin- 23 (IL- 23)/ 
IL- 17 pathway plays a major role in PsA/SpA immunopathogen-
esis (2,3). Therapies targeting IL- 17A show clinical efficacy in 
patients with PsA and those with AS (4,5), while several genetic 
loci implicated in the IL- 17/IL- 23 axis, including IL12B (IL- 12p40), 
IL23R, and TRAF3IP2 (Act1) are associated with PsA and AS sus-
ceptibility (6,7). To date, the majority of studies have focused on 
identifying IL- 17A–producing CD4+ T (Th17) cells or group 3 innate 
lymphoid cells in the inflamed joints of patients with PsA/SpA, yet 
the strong association of major histocompatibility complex (MHC) 
class I and other CD8+ T cell/MHC class I–related loci (RUNX3, 
ERAP1/2) suggests that CD8+ T cells play an important role in 
PsA/SpA (7–9). We previously demonstrated the enrichment of 
IL- 17A–expressing CD8+ T (Tc17) cells in the synovial fluid (SF) 
of patients with PsA (10); Tc17 cells have also been observed in 
the SF of patients with juvenile idiopathic arthritis (JIA) (11) and at 
the site of inflammation in other immune- mediated inflammatory 
diseases (for review, see refs. 2 and 12). Recent murine models 
and transcriptional analysis of healthy human spleen Tc17 cells 
have shed light on the function of Tc17 cells (13,14). However, 
functional and molecular analysis of human synovial Tc17 cells is 
essential to elucidate the role of synovial Tc17 cells in PsA/SpA 
pathogenesis.
The enrichment of Tc17 in the inflamed joint raises the ques-
tion of whether these cells migrate into the joint or are persis-
tently present. Recently, a novel subset of CD8+ effector T cells 
enriched in tissue compartments without significant presence in 
the blood has been described (15). These tissue- resident mem-
ory T (Trm) cells are characterized by expression of CD69 and 
CD103, defined by a core transcriptional signature (16), and have 
the potential to produce proinflammatory cytokines including 
IL- 17A, IL- 22, and interferon- γ (IFNγ), as well as granzymes and 
perforin (for review, see refs. 17 and 18). In humans, Trm cells have 
been observed in skin, lung, gut, and brain tissue, and a recent 
study demonstrated the presence of CD8+ T cells with a tissue- 
resident memory phenotype in the SF of patients with JIA (11). As 
such, Trm cells are hypothesized to contribute to the immunopatho-
genesis of human immune- mediated inflammatory disease. How-
ever, if and how Tc17 and Trm cells relate to each other is not well 
established.
To enhance our understanding of the function and molec-
ular biology of human IL- 17A+CD8+ T cells, we performed 
extensive phenotypic, molecular, and functional profiling of 
human Tc17 cells derived from PsA SF. Using flow cytome-
try, T cell receptor (TCR) sequencing, Luminex, and RNA- Seq 
analysis, we demonstrated that PsA synovial IL- 17A+CD8+ T 
cells have a polyclonal TCR repertoire, a polyfunctional, proin-
flammatory cytokine profile, and many hallmarks of Trm cells. 
These features position Tc17 cells as relevant contributors to 
the initiation or perpetuation of chronic inflammation in PsA, 
and possibly other SpA or IL- 17A/HLA class I–associated 
inflammatory diseases.
MATERIALS AND METHODS
Study subjects. Peripheral blood (PB) and SF samples were 
obtained from patients with PsA or other types of peripheral SpA 
(AS/nonradiographic axial SpA, reactive arthritis, and enteropathic 
arthritis) who were seen in the Rheumatology Department of Guy’s 
Hospital. Patients fulfilled the Classification of Psoriatic Arthritis 
Study Group or American College of Rheumatology/European 
League Against Rheumatism 2010 criteria (19,20). The demo-
graphic and clinical characteristics of patients are shown in Supple-
mentary Table 1, available on the Arthritis & Rheumatology web site 
at http://onlin elibr ary.wiley.com/doi/10.1002/art.41156/ abstract. All 
subjects provided written informed consent. Ethics approval was 
obtained from Bromley Research Ethics Committee (06/Q0705/20) 
and Harrow Research Ethics Committee (17/LO/1940).
Cell isolation. Mononuclear cells (PB mononuclear cells 
[PBMCs] and SF mononuclear cells [SFMCs]) were isolated using 
Lymphoprep (Axis- Shield) and washed in culture medium (RPMI 
1640 supplemented with 10% fetal calf serum [FCS] + 1% penicillin/
streptomycin/l- glutamine). Cells were cryopreserved and stored in 
liquid nitrogen in culture medium supplemented with 50% FCS and 
10% dimethyl sulfoxide (all from ThermoFisher).
Flow cytometric analysis. Thawed cells were rested for 1 
hour at 37°C in an atmosphere of 5% CO2. For intracellular stain-
ing, samples were stimulated with phorbol myristate acetate (PMA; 
50 ng/ml) and ionomycin (750 ng/ml) (both from Sigma- Aldrich) in 
the presence of GolgiStop (BD Biosciences) for 3 hours at 37°C in 
an atmosphere of 5% CO2. Cells were stained with eFluor 780 Via-
bility Dye (eBioscience), and surface staining was performed at 4°C. 
Cells were fixed with 2% paraformaldehyde and permeabilized using 
0.5% saponin (Sigma- Aldrich). Antibodies are listed in Supplemen-
tary Table 2, available on the Arthritis & Rheumatology web site at 
http://onlin elibr ary.wiley.com/doi/10.1002/art.41156/ abstract. Sam-
ples were acquired using an LSRFortessa system (BD Biosciences). 
Data were analyzed using FlowJo (version 10; Tree Star).
TCRβ sequencing. Extracted DNA (Qiagen) was subjected 
to bias- controlled amplification of V–D–J rearrangements followed 
by high- throughput sequencing (immunoSEQ; Adaptive Biotech). 
Data from productive reads (sequence level) were analyzed using 
an immunoSEQ analysis platform (Adaptive Biotech). Clonality was 
defined as 1 – Pielou’s evenness and ranged from 0 (indicating a 
highly polyclonal repertoire) to 1 (indicating a monoclonal repertoire). 
Overlap was determined using the Morisita index, with possible 
scores ranging from 0 (indicating no similarity between 2 popula-
tions) to 1 (indicating complete similarity between 2 populations).
Cell sorting. For Trm cell sorting, SFMCs were stained with 
eFluor 780 and CD3, CD4, CD8, CD14, CD69, and CD103 antibod ies 
(Supplementary Table 2, available on the Arthritis & Rheumatology 
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web site at http://onlin elibr ary.wiley.com/doi/10.1002/art.41156/ 
abstract). After sorting, CD8+ Trm subsets were stimulated, fixed, 
and permeabilized before intracellular cytokine staining for IL- 17A 
and IFNγ. For sorting of cytokine- producing cells, magnetically 
isolated (Miltenyi Biotec) CD3+ T cells were stimulated for 1.5 hours 
at 37°C with PMA (50 ng/ml) and ionomycin (750 ng/ml) before 
staining using an IL- 17A and, where indicated, IFNγ cytokine secre-
tion assay (Miltenyi). To identify cytokine- producing T cell subsets, 
Figure 1. Enrichment of T cells positive for interleukin- 17A (IL- 17A) and T cell receptor αβ (TCRαβ) in the synovial fluid (SF) of patients 
with spondyloarthritis (SpA). A and B, Representative staining (A) and cumulative data (B) showing the frequencies of IL- 17A+ cells among 
CD3+CD8+ T cells in paired peripheral blood mononuclear cells (PBMCs) and SF mononuclear cells (SFMCs) from patients with psoriatic 
arthritis (PsA; n = 18), other peripheral SpA (n = 14), or rheumatoid arthritis (RA; n = 6) after 3 hours of stimulation in the presence of phorbol 
myristate acetate, ionomycin, and GolgiStop. P values were determined by Wilcoxon’s matched pairs signed rank test. C and D, Representative 
staining (C) and cumulative data (D) showing the frequencies of IL- 17A+CD8+ T cells expressing TCRαβ (n = 8), TCRγδ (n = 9), CD56 (n = 7), 
and Vα7.2 (n = 6) in PsA SF (stimulated as described in A and B). E and F, Representative staining (E) and frequencies (F) of IL- 17A+CD8+ 
T cells expressing CD45RA and/or CD27 in PsA SFMCs (n = 6) (stimulated as described in A and B). G and H, Representative staining (G) 
and cumulative data (H) showing the frequencies of IL- 17A+CD8+ T cells expressing programmed death 1 (PD- 1) or HLA–DR in PsA patients 
(n = 6). In D and H, symbols represent individual patients, bars show the median and interquartile range. Color figure can be viewed in the online 
issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.41156/abstract.
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cells were counterstained with eFluor 780, and anti- CD3, CD8, 
CD14, and CD4 antibodies. Cells were sorted using a BD FACSAria 
and acquired using an LSRFortessa system (BD  Biosciences).
RNA sequencing and quantitative reverse transcrip­
tase–polymerase chain reaction (qRT­ PCR). Libraries were 
prepared by Genewiz and sequenced on a HiSeq 2500 platform 
(Illumina) at a depth of 28–40M reads. Low- quality bases and 
adapters (phred score <20) were trimmed using TrimGalore!, and 
reads were aligned (hg38) using RNA STAR. Paired reads were 
quantified using featureCounts. Principal components analysis 
and statistical comparison of gene expression were performed 
using DESeq2. RNAseq data are available via GSE137510.
For qRT- PCR, total RNA was extracted from sorted cell sub-
sets (Qiagen). Complementary DNA (cDNA) was generated using 
a high- capacity cDNA reverse transcription kit (ThermoFisher). 
RT- PCR was performed using a SensiFAST SYBR kit (Bioline) and 
primers from Integrated DNA Technologies (listed in Supplemen-
tary Table 3, available on the Arthritis & Rheumatology web site 
at http://onlin elibr ary.wiley.com/doi/10.1002/art.41156/ abstract).
Luminex assay and CXCL16 enzyme­ linked immuno­
sorbent assay (ELISA). Supernatants were obtained from 
sorted T cell subsets cultured for 24 hours in culture media. A cus-
tom magnetic Luminex (Bio- Techne) was analyzed on a Luminex 
FlexMap  3D platform. Serum and SF were analyzed using a 
CXCL16 ELISA (Bio- Techne).
Graphics and statistical analysis. Statistical analysis and 
graphic illustration were performed using either GraphPad Prism 
(version 7) or ggplot2 (R version 3.5.2). Results are expressed 
as the median and interquartile range. Wilcoxon’s matched pairs 
signed rank test or Friedman’s multiple comparisons test were 
performed.
RESULTS
Tc17 cells are polyclonal TCRαβ+ memory cells 
enriched in PsA/SpA joints. To determine whether synovial 
Tc17 cells are enriched only in PsA or are also enriched in other 
SpA types, we stimulated paired PBMCs and SFMCs from patients 
with PsA, patients with other types of SpA, and patients with rheu-
matoid arthritis (RA) ex vivo with PMA/ionomycin and assessed the 
frequency of IL- 17A+CD8+ T cells by flow cytometry (Figures 1A 
and B). (The gating strategy is shown in Supplementary Figure 1, 
available on the Arthritis & Rheumatology web site at http://onlin 
elibr ary.wiley.com/doi/10.1002/art.41156/ abstract.) Low frequen-
cies of Tc17 cells were detected in PBMCs from patients with PsA, 
those with other types of SpA, and those with RA (median 0.1%), 
with no significant differences observed between these groups. 
The frequencies of Tc17 cells were significantly increased in 
SFMCs compared to PBMCs in patients with PsA (P < 0.0001) and 
those with other types of SpA (P = 0.0009), but not those with RA 
(P = 0.16). The frequencies of Th17 cells were similar between the 
3 disease groups (Supplementary Figure 1B).
Synovial Tc17 cells predominantly comprised TCRαβ+ cells, 
with small proportions of mucosal- associated invariant T cells 
(Vα7.2+), TCRγδ, and natural killer T cells (Figures  1C and D). 
Over 98% of synovial Tc17 cells exhibited a memory phenotype 
(CD45RA−CD27+/− or CD45RA+CD27-) (Figures 1E and F), while 
a considerable proportion of Tc17 cells expressed the immunoin-
hibitory receptor programmed death 1 (PD- 1; median 65%) and 
activation marker HLA–DR (median 51%), suggesting that these 
cells previously experienced antigen stimulation (Figures 1G and H).
The presence of clonally restricted memory CD8+ T cells 
with features of antigen- specific expansion has been described in 
the SF, synovial tissue, and skin of patients with PsA (21–23). To 
investigate whether synovial Tc17 cells are also clonally restricted 
in PsA, bulk memory (CD45RA−CD27+/− and CD45RA+CD27−), 
IL- 17A+IFNγ+/− (Tc17), and IL- 17A−IFNγ+ (Tc1) memory CD8+ T 
cells were sorted from the SF of PsA patients. (The gating strategy 
is shown in Supplementary Figure 2, available on the Arthritis 
& Rheumatology web site at http://onlin elibr ary.wiley.com/
doi/10.1002/art.41156/ abstract.) TCRβ sequencing showed that 
synovial Tc17 cells have a diverse TCR repertoire (Figure 2A) with 
a low clonality score (Pielou’s evenness), which was similar to that 
for synovial Tc1 and bulk memory CD8+ T cells (Figures 2A and B). 
For 2 patients, a substantial proportion of the clones found in syn-
ovial Tc17 cells were also present in the synovial Tc1 population, 
resulting in a Morisita overlap index >0.9 (Figures 2C and D). The 
third patient had a lower number of productive templates, which 
may have resulted in a low Morisita score.
Molecular analysis of synovial Tc17 cells reveals com­
monalities in transcriptional profile with Th17 and Tc1 
cells. Recent transcriptional analysis of healthy human spleen 
Tc17 cells revealed a distinct molecular profile compared to IL- 17−
CD8+ T cells or Th17 cells (14). To determine the molecular pro-
file of Tc17 cells from the inflamed PsA joint, we sorted highly pure 
Tc17, Tc1, and Th17 cells from the SFMCs of patients with PsA for 
RNA  sequencing. (The gating strategy is shown in Supplementary 
Figure 3, available on the Arthritis & Rheumatology web site at http://
onlin elibr ary.wiley.com/doi/10.1002/art.41156/ abstract.) Accurate 
sorting was confirmed by the normalized gene counts of IL17A and 
IFNG for each of the populations (Supplementary Figure 3B).
Principal components analysis showed a degree of gene 
expression heterogeneity between synovial Tc17 cells from dif-
ferent patients. In 2 of 3 patients, the synovial Tc17 cells clustered 
separately from the Th17 cells but close to the Tc1 cells (Fig-
ures 3A and B), suggesting that a proportion of the transcriptional 
profile is shared between synovial Tc17 and Tc1 cells. In total, 80 
genes were differentially expressed between the synovial Tc17 
and Tc1 subsets (≤1% false discovery rate; fold change >2). 
MA plots indicating the 10 genes up- regulated to the greatest 
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degree and the 10 genes down- regulated to the greatest degree 
are shown in Figure 3C. Several genes relating to a type 17 T 
cell response (IL17A, IL17F, RORC, IL23R, CCR6, and KLRB1) 
were elevated in synovial Tc17 cells compared to synovial Tc1 
cells (Figures 3C and E). When synovial Tc17 cells were com-
pared to synovial Th17 cells, 145 genes were found to be differ-
entially expressed (Figure 3D). Genes that were up- regulated in 
synovial Tc17 cells compared to Th17 cells included CD8A and 
CD8B, confirming our gating strategy, plus genes associated 
with cyto lytic activity (GRZA, GRZB, and PRF1) (Figures  3D 
and F). Expression levels of TCF7 (encoding T cell factor 1), 
recently identified as a transcription regulator of mouse Tc17 
cells through repression of MAF BZIP transcription factor and 
retinoic acid receptor–related orphan nuclear receptor γt (14), 
were low in synovial Tc17 cells (Supplementary Figure 3C).
We confirmed the transcription data for the type 17 T cell 
markers CCR6 and CD161 at the protein level by flow cytome-
try. A high frequency of synovial Tc17 cells coexpressed CCR6 
or CD161, at levels comparable to those in synovial Th17 cells. 
In contrast, only limited proportions of synovial IL- 17A−CD8+ 
or IFNγ+CD8+ T cells expressed these molecules (Figures 4A 
and B). A viSNE analysis showed that CCR6 and CD161 were 
coexpressed by Tc17 cells (Figure 4C) (results are representative 
of those for 7 patients). Notably, this analysis also revealed that 
expression of CCR6 and CD161 was not restricted to the IL- 
17A+ population, i.e., these markers do not exclusively define 
IL- 17A expression in synovial CD8+ T cells. Quantitative RT- 
PCR analysis further confirmed that transcript levels of RORC 
and IL23R in the synovial Tc17 population were comparable 
to those in Th17 cells, and higher than those in IL- 17A−CD8+ 
T cells (which contains IFNγ+CD8+ T cells) (Figure 4D).
Frequencies of Tc17 cells expressing granzyme A, gran-
zyme B, CD107a, or perforin were variable but enhanced 
compared to synovial Th17 cells, while they were compara-
ble to those among synovial Tc1 cells (Figures 4E and F). It 
should be noted, however, that limited expression of  perforin 
Figure 2. Diverse T cell receptor (TCR) repertoire in synovial Tc17 cells. A, Representative pie charts with segments representing the frequencies 
of all TCRβ sequences in bulk memory CD8+ T cells, CD8+ T cells positive for interleukin- 17A (IL- 17A), and CD8+ T cells negative for IL- 17A 
and positive for interferon-­γ (IFNγ) in a patient with psoriatic arthritis (PsA). B, Clonality score (defined as 1 − Pielou’s evenness) for bulk memory 
CD8+, IL- 17A+CD8+, and IL- 17A−IFNγ+CD8+ T cells in PsA synovial fluid samples (n = 3). Symbols represent individual patients; bars 
show the median and interquartile range. C and D, Dot plots (C) and Morisita’s index (D) showing the degree of clonal overlap between 
IL- 17A+CD8+ and IL- 17A−IFNγ+CD8+ T cells in 3 patients with PsA. Color figure can be viewed in the online issue, which is available 
at http://onlinelibrary.wiley.com/doi/10.1002/art.41156/abstract.
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and lysosomal- associated membrane protein 1 (LAMP- 1)/
CD107a was observed in synovial Tc17 cells, suggesting 
that these cells may not have full cytotoxic capability.
Tc17 cells have hallmarks of Trm cells. The observation 
that Tc17 cells with a memory phenotype are enriched in the joint, 
but not the blood, in PsA patients prompted us to investigate 
Figure 3. Transcriptional profile of synovial Tc17 cells compared to Tc1 cells and Th17 cells. A and B, Principal components analysis of 
the transcriptome of IL-17A+CD8+, IFNγ+CD8+, and IL-17A+CD4+ T cells from the synovial fluid of PsA patients (n = 3) by cell type (A) and 
by patient (B). C and D, MA plots showing genes that were significantly up- regulated or down- regulated in synovial IL- 17A+CD8+ T cells 
compared to IFNγ+CD8+ T cells or IL- 17A+CD4+ T cells (n = 3). E and F, Selected gene expression profiles shown as average gene expression 
values (fragments per kilobase million [FPKM]) in synovial IL-17A+CD8+ compared to IFNγ+CD8+ T cells or CD4+IL-17A+ T cells (n = 3). PC1 = 
principal component 1 (see Figure 2 for other definitions).
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Figure 4. Synovial Tc17 cells have functional hallmarks of Th17 and Tc1 cells. A and B, Representative staining (A) and cumulative data 
(B) showing the frequencies of IL- 17A+CD8+, IL- 17A+CD4+, IL- 17A−CD8+, and IFNγ+CD8+ T cells expressing CCR6 and CD161 in synovial 
fluid mononuclear cells (SFMCs) from patients with PsA (solid symbols) and patients with other types of spondyloarthritis (open symbols) 
(n = 7–9). C, Representative viSNE plot showing concomitant expression of IL- 17A, CCR6, and CD161 among CD8+ T cells in PsA SFMCs. 
Representative results from 1 of 7 patients are shown. D, Gene expression levels of RORC and IL23R, normalized to the average values for 
UBC and 18S in sorted IL- 17A+CD8+, IL- 17A−CD8+, and IL- 17A+CD4+ T cells from PsA SFMCs (n = 4). E and F, Representative staining 
(E) and cumulative data (F) showing the frequencies of IL- 17A+CD8+, IFNγ+CD8+, and IL- 17A+CD4+ T cells expressing granzyme A (GrzA; 
n = 4), granzyme B (GrzB; n = 9), CD107a/lysosomal- associated membrane protein 1 (LAMP- 1; n = 6), and perforin (n = 6) in PsA SFMCs. 
P values were determined by Friedman’s multiple comparisons test. In B, D, and F, symbols represent individual patients; bars show the median 
and interquartile range. See Figure 2 for other definitions. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.
wiley.com/doi/10.1002/art.41156/abstract.
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Figure  5. Synovial Tc17 cells form part of the synovial tissue- resident T cell compartment. A, Selected tissue- resident memory T (Trm) 
cell–associated gene expression profiles of sorted synovial IL- 17A+CD8+ T cells compared to IL- 17A+CD4+ T cells (n = 3). B and C, 
Representative staining (B) and cumulative data (C) showing the frequencies of IL- 17A+CD8+ T cells expressing CD103/αE integrin 
(n = 12), β7 integrin (n = 7), CD49a/very late activation antigen 1 (n = 9), or cutaneous lymphocyte antigen (CLA; n = 12) in PsA synovial fluid 
mononuclear cells (SFMCs), after 3 hours of stimulation in the presence of phorbol myristate acetate (PMA), ionomycin, and GolgiStop. D and 
E, Representative staining (D) and cumulative data (E) showing the frequencies of CD69+CD103+, CD69+CD103−, and CD69−CD103+ Trm 
cells among synovial CD3+CD8+ and CD3+CD4+ T cells (n = 12). F–H, PsA SF cells (n = 3) were sorted into CD69+CD103+, CD69+CD103−, 
CD69−CD103+, and CD69−CD103− CD8+ T cells. Sorted subsets were stimulated with PMA and ionomycin in the presence of GolgiStop for 
3 hours. F and G, Representative staining showing IL- 17A (F) and IFNγ (G) expression within the 4 sorted subsets. H, Proportion of IL- 17A+ 
cells (left; n = 3) and IFNγ+ cells (right; n = 2) in each Trm subset, as a fraction of total IL- 17A–expressing or IFNγ- expressing cells. In C and 
E, symbols represent individual patients; bars show the median and interquartile range. FPKM = fragments per kilobase million (see Figure 2 
for other definitions). Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.41156/
abstract.
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whether synovial Tc17 cells from the inflamed joint expressed 
markers of tissue residency. Molecular profiling revealed that genes 
reported to be transcriptional hallmarks of Trm cells (e.g., ITGAE 
[encoding CD103], ZNF683 [encoding HOBIT], CRTAM, and low 
levels of S1PR1) (16) were differentially expressed between 
synovial Tc17 and Th17 cells (Figure  5A). We confirmed the 
Figure 6. Synovial Tc17 cells are polyfunctional proinflammatory cells characterized by high expression of CXCR6. A and B, Representative 
staining (A) and cumulative data (B) showing the frequencies of IL- 17A+CD8+ (left) and IL- 17A+CD4+ (right) T cells expressing IFNγ (n = 12), tumor 
necrosis factor (TNF; n = 12), granulocyte–macrophage colony- stimulating factor (GM- CSF; n = 9), IL- 21 (n = 6), IL- 22 (n = 6), and IL- 10 (n = 8) in 
synovial fluid mononuclear cells (SFMCs) from patients with PsA (solid symbols) or other types of spondyloarthritis (open symbols). C, Proportion of 
IL- 17A+CD8+ T cells expressing IL- 17A alone, IL- 17A plus IFNγ or TNF, and IL- 17A plus IFNγ and TNF. D, IL- 17A, IFNγ, TNF, GM- CSF, IL- 21, IL- 22, 
and IL- 10 secretion by sorted synovial IL- 17A+CD8+ T cells (n = 4). E, Top, Venn diagram showing the number of significantly up- regulated genes 
(P < 0.01) in IL- 17A+CD8+ T cells versus IFNγ+CD8+ T cells and in IL- 17A+CD8+ T cells versus IL- 17A+CD4+ T cells. Bottom, Heatmap showing 
genes that were consistently up- regulated in all patients. F, Representative dot plot and histograms (top) and cumulative data (bottom) showing 
the percentage of CXCR6+ cells and CXCR6 expression levels in PsA synovial IL- 17A+CD8+ T cells, IFNγ+CD8+ T cells, and IL- 17A+CD4+T cells 
(n = 6). P values were determined by Friedman’s multiple comparisons test. G, CXCL16 levels in paired PsA serum and SF samples (n = 12) as 
measured by enzyme- linked immunosorbent assay. P value was determined by Wilcoxon’s matched pairs signed rank test. In C and D, bars show 
the median and interquartile range. MFI = mean fluorescence intensity (see Figure 2 for other definitions). Color figure can be viewed in the online 
issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.41156/abstract.
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expression of the Trm cell marker CD103 (αE integrin) on a high 
proporion of joint- derived Tc17 cells by flow cytometry (Figures 5B 
and C). CD69, which is also commonly used as a Trm marker, is 
up- regulated upon PMA/ionomycin stimulation and was therefore 
not evaluated. Since Tc17 cells have been identified in the gut and 
the skin (24–27), sites that can also be affected in PsA/SpA, we 
assessed markers for the gut- related molecule β7 integrin (which 
is normally coexpressed with αE integrin) and the skin- related 
adhesion/homing molecules cutaneous lymphocyte antigen 
(CLA) and CD49a (very late activation antigen [VLA- 1]). Consid-
erable proportions of synovial Tc17 cells coexpressed β7 integrin, 
CD49a/VLA- 1, and to a lesser extent CLA (Figures 5B and C).
Based on these findings, we examined the presence of Trm 
cells using the markers CD69 and/or CD103 in unstimulated 
SFMCs from PsA patients (Figures 5D and E). Within the CD8+ 
T cell population, on average 11% of cells were CD69+CD103+ 
(range 2–16%), 26% of cells were CD69+CD103− (range 3.2–
54%), and 6% of cells were CD69−CD103+ (range 1.29–16%). In 
the CD4+ compartment, 26% of the cells were CD69+CD103−, 
while CD103 expression was negligible (expressed by <1% of 
CD4+ T cells). These data indicate that CD103+ Trm cells in the 
inflamed PsA joint are typically CD8+ T cells.
To directly demonstrate that CD8+ Trm cells contain IL- 17A–
producing cells, we sorted synovial CD8+ T cells from PsA patients 
into highly pure CD69+CD103+, CD69+CD103−, CD69−CD103+, 
and CD69−CD103− subsets. (The gating strategy is shown in 
Supplementary Figure 4, available on the Arthritis & Rheumatology 
web site at http://onlin elibr ary.wiley.com/doi/10.1002/art.41156/ 
abstract.) The sorted cells were then stimulated ex vivo and stained 
for IL- 17A and IFNγ (Figures 5F and G). After normalizing for total 
cytokine expression, we observed that the CD69+CD103+CD8+ 
T cell population contained the highest frequency of IL- 17A+ cells, 
followed by cells expressing either CD69 or CD103 only, while 
CD69−CD103−CD8+ T cells contained minimal IL- 17A+ cells 
 (Figure 5H). In contrast, frequencies of IFNγ+ cells were distributed 
more equally among the 4 sorted cell subsets. We also found a 
significant correlation between the presence of IL- 17A+CD8+ T 
cells and CD69+CD103+ Trm cells in the SF, further supporting 
a relationship between these 2 cell populations (Supplementary 
 Figure 5, available on the Arthritis & Rheumatology web site at 
http://onlin elibr ary.wiley.com/doi/10.1002/art.41156/ abstract). 
Taken together, these data indicate that synovial Trm cells are 
enriched for IL- 17A expression and that Tc17 cells form part of the 
Trm cell pool in the inflamed synovial joints in PsA.
Synovial Tc17 cells are polyfunctional inflamma­
tory cells characterized by high expression of CXCR6. 
Finally, we sought to determine the functional potential of syn-
ovial Tc17 cells. For this, we assessed the coexpression and 
secretion of proinflammatory and antiinflammatory cytokines by 
flow cytometry and Luminex assay. A substantial proportion of 
synovial Tc17 cells coexpressed proinflammatory IFNγ, TNF, and 
granulocyte–macrophage colony- stimulating factor (GM- CSF), 
while IL- 21 was coexpressed by <20% of Tc17 cells. IL- 22 and 
antiinflammatory IL- 10 were found to be either absent or expressed 
by only a small proportion of Tc17 cells (Figures  6A and B). 
IL- 17F was found to be coexpressed by only a small propor-
tion of Tc17 cells (Supplementary Figure 6B, available on the 
Arthritis & Rheumatology web site at http://onlin elibr ary.wiley.
com/doi/10.1002/art.41156/ abstract). The cytokine coexpres-
sion profile of synovial Tc17 cells closely resembled the cytokine 
profile of synovial Th17 cells (Figure 6B), while this profile was not 
shared by synovial IL- 17A−CD8+ or IFNγ+CD8+ T cell subsets 
(Supplementary Figure 6A). Overall, synovial Tc17 cells displayed 
a polyfunctional cytokine profile with a sizable proportion of cells 
(median 36%) expressing IL- 17A, IFNγ, and TNF concomitantly 
(Figure  6C). This concomitant cytokine production was also 
observed in the Luminex analysis: sorted IL- 17A+CD8+ T cells 
from the SF of patients with PsA produced IL- 17A, IFNγ, TNF, 
GM- CSF, and IL- 22, with low levels of IL- 21 and IL- 10, during 
a 24- hour culture (Figure 6D). (The gating strategy is shown in 
Supplementary Figure 7, available on the Arthritis & Rheuma-
tology web site at http://onlin elibr ary.wiley.com/doi/10.1002/
art.41156/ abstract.)
Finally, we investigated whether Tc17 cells from the inflamed 
PsA joint express a unique set of markers. For this analysis, we 
compared the transcriptional profile of synovial Tc17 cells to the 
profiles of both synovial Tc1 and Th17 cells, to determine which 
markers are uniquely up- regulated in synovial Tc17 cells. Bioinfor-
matics analysis revealed that 15 genes were up- regulated in both 
comparisons, suggesting that synovial Tc17 cells have a small 
unique transcriptional profile in comparison to synovial Tc1 and 
Th17 cells (Figure 6E). Of these 15 genes, 6 were found to be 
consistently up- regulated in all 3 patients: CXCR6, NCR3, CHN1, 
LINC02195, LINC01871, and GOLIM4. Since CXCR6 is part of 
the Trm gene signature (16), we validated CXCR6 at the protein 
level and found that PsA synovial Tc17 cells indeed expressed 
CXCR6 at the highest level and contained the highest proportion 
of CXCR6- expressing cells as compared to their synovial Tc1 and 
Th17 counterparts (Figure 6F). In addition, levels of CXCL16, the 
ligand for CXCR6, were significantly increased in PsA SF versus 
paired serum samples (Figure 6G).
DISCUSSION
We previously described an enrichment of IL- 17A+CD4− (the 
majority of which were CD8+) T cells in the SF, compared to the 
PB, in patients with PsA (10). In this study we showed that fre-
quencies of IL- 17A+CD8+ T cells were also increased in the SF of 
patients with other types of SpA, and confirmed that these cells 
were not increased in patients with RA (10). These findings add 
to the growing evidence that CD8+ T cells and the IL- 17/IL- 23 
axis are relevant to the immunopathogenesis of PsA/SpA (2). We 
demonstrated that the vast majority of PsA synovial Tc17 cells are 
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memory cells, indicated by a CD45RA−PD- 1+HLA–DR+ profile, 
as well as TCRαβ bearing, suggesting that these cells are MHC 
class I restricted and antigen- experienced.
Previous studies demonstrated oligoclonal expansion of 
joint- derived bulk T cells in PsA (21–23). Our TCRβ sequencing 
of synovial Tc17 cells, although limited in sample size, showed 
that while some T cell clones occupied >5% of the total TCR rep-
ertoire, the majority of Tc17 cells, as well as of the bulk memory 
CD8+ T cells and Tc1 cells, had a polyclonal TCR repertoire. One 
reason for the differences observed between the previous studies 
and our own could be patient disease activity. A previous study 
investigating the clonality of psoriatic skin–derived CD8+ T cells 
showed that the TCR repertoire is polyclonal in active disease, 
while in resolved disease only a few dominant clones persist (28). 
We obtained SF effusions from joints with active inflammation, 
which could explain the polyclonal repertoire observed. It would 
be of interest to investigate whether a polyclonal repertoire is also 
observed in joints in which PsA has resolved; however, this would 
require a synovial biopsy study design since noninflamed joints 
rarely contain sufficient SF for aspiration.
A notable observation in our analysis was the extensive shar-
ing of T cell clones between the synovial Tc17 and Tc1 popu-
lations. Our RNA- Seq analysis also showed significant overlap 
in transcriptional profile between Tc17 and Tc1 cells. A possible 
explanation for these findings is that synovial Tc17 and Tc1 cells 
may have shared ancestry, which raises the question of plasticity 
between these subsets. Adoptive transfer of in vitro generated 
Tc17 cells into recipient mice showed that Tc17 cells can switch 
to an IL- 17A–negative Tc1 profile (29–31). A direct demonstration 
of this phenomenon came from an elegant IL- 17A fate- mapping 
study using reporter donor IL- 17CreRosa26eYFP (13). That study 
showed that Tc17 cells developed early after allogeneic stem 
cell transplantation in both lymphoid tissue and graft- versus- host 
disease target organs. However, their production of IL- 17A was 
transient, while IFNγ production was largely maintained, a process 
defined by the surrounding cytokine milieu. A similar capacity to 
transition to IFNγ production and Th1 phenotype had previously 
been shown for mouse Th17 cells (32). These fate- mapping data, 
taken together with our findings on shared TCR and transcrip-
tional profiles and the observation that a high frequency of synovial 
Tc17 cells express IFNγ, suggest that synovial Tc17 cells can tran-
sition to a Tc1- like cytokine profile, as was previously suggested 
for Th17 and Th1 cells in the joints of patients with JIA (33). If this 
scenario is indeed the case, then one implication of this finding 
would be that the percentage of IL- 17A+CD8+ T cells detected 
by flow cytometry may underrepresent the contribution that Tc17 
cells make or have made to the synovial T cell compartment.
In addition to Tc17/Tc1 overlap, we observed a phenotypic 
and molecular overlap between Tc17 and Th17 cells in PsA, as 
evaluated by RNA- Seq, qRT- PCR, and flow cytometry. Two mark-
ers typically expressed by Th17 cells, CCR6 and CD161 (34–36), 
are coexpressed by a large proportion of synovial Tc17 cells. 
 Furthermore, expression of IL23R by synovial Tc17 cells indicates 
that IL- 23 may be involved in the generation or maintenance of 
these cells, while elevated RORC transcript expression suggests 
that RORγt may at least play a part in IL- 17A regulation in these 
cells. These data indicate that Tc17 cells may be regulated by sim-
ilar pathways as Th17 cells.
The relatively limited sample sizes in the TCR and RNA- Seq 
analysis could be considered a limitation of our study. However, 
given the challenges in obtaining sufficient numbers from small 
populations of immune cells, this number of samples (n = 3) is not 
uncommon in studies of human tissue- derived cells. Additionally, 
many of our RNA- Seq results were independently validated at the 
protein or RNA level. A further limitation of our study is that we 
did not have access to synovial tissue samples from patients with 
PsA. Nonetheless, the work presented here provides an important 
basis for future studies aimed at comparing the phenotype and 
molecular profile of SF- and synovial tissue–derived Tc17 cells.
A key novel finding of our study is that synovial Tc17 cells 
are part of the Trm cell compartment and express molecules that 
prevent egress from the inflamed tissue into the blood. Trm cells 
are rapidly emerging as potential contributors to inflammation in 
several immune- mediated inflammatory diseases (17,37). To our 
knowledge, this is the first study to show that Tc17 cells form part 
of the synovial Trm pool, and only the second description of Trm- 
like cells in the context of human immune- mediated arthritis (11). 
Our data also show that a high proportion of synovial Tc17 cells 
express markers typically associated with homing to the skin or 
gut. This finding could indicate that synovial Tc17 cells have tro-
pism for these tissues as well as for the synovial compartment, 
and indeed, the presence of Tc17 cells has been described in 
both the skin and the gut (24,25,27). An alternative explanation 
could be that synovial Tc17 cells expressing these markers have 
enhanced adherence to the surrounding joint tissue, as both CLA 
and CD49a ligands (E- selectin and type IV collagen, respectively) 
are present in the synovial tissue (38,39). β7 integrin, which is 
expressed by a large proportion of synovial Tc17 cells, can form a 
heterodimer with the Trm cell marker CD103 (αE integrin), which is 
expressed by Tc17 cells. The product, αEβ7 integrin, exclusively 
binds E- cadherin, a structural protein expressed in the synovi- 
al joint and fluid in patients with inflammatory arthritis (39,40). 
Interaction of synovial Tc17 cells with the surrounding tissue and 
extracellular matrix in the fluid combined with lack of response to 
exit cues (e.g., S1P1) could represent one way in which Tc17 cells 
are retained in the synovial joint and contribute to perpetuation or 
re- initiation of inflammation.
Residence of synovial Tc17 cells in the inflamed tissue may 
be further enhanced by their high expression of CXCR6, a marker 
of Trm cells (16), in combination with the increased levels of 
CXCL16 in the PsA synovial joint. CXCL16 has chemotactic and 
angiogenic properties and can be produced as a soluble medi-
ator or as a transmembrane- bound chemokine by monocytes, 
macrophages, and dendritic cells. Evidence of increased CXCL16 
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and CXCR6 expression at the site of inflammation was reported 
previously in the context of RA and psoriasis, and CXCL16 was 
shown to enhance recruitment of inflamed tissue- derived CXCR 
6- expressing T cells (41–43). Furthermore, CXCL16 blockade or 
CXCR6 deficiency led to reduced arthritis scores and lower IFNγ/
IL- 17 production in an experimental model of arthritis (42,44). 
Taken together, these data suggest that the increased CXCR6 
expression on synovial Tc17 cells may contribute to their recruit-
ment and persistence in the inflamed PsA joint.
Functionally, our data indicate that synovial Tc17 cells are poly-
functional and actively secrete several proinflammatory cytokines 
(IFNγ, TNF, GM- CSF, IL- 21, and IL- 22) in parallel with IL- 17A, but 
little IL- 10 or IL- 17F. IFNγ, TNF, and GM- CSF have all been shown 
to act synergistically with IL- 17A to promote inflammation. In a 
recent study by Wade et al, polyfunctional CD8+ T cells were also 
found to be enriched in the PsA synovium, although enrichment 
was not observed for single cytokine–producing T cells, including 
IL- 17A+CD8+ T cells (45). Concordant with their proinflammatory 
cytokine production, Tc17 cells coexpressed cytolytic molecules 
granzyme A and granzyme B at levels comparable to those in sy- 
novial Tc1 cells. However, Tc17 cells lacked significant expression 
of other cytolytic machinery (perforin and LAMP- 1). Most studies 
to date in both mice and humans have shown that Tc17 cells 
lack cytolytic function (29,31,46,47), although some evidence for 
cytotoxic function has been reported (24,48). An interesting alter-
native interpretation of our data is that the secretion of granzymes 
is not cytolytic but leads to extracellular matrix degradation or 
promotion of inflammation (49,50). Taken together, these data 
show that Tc17 cells are armed with an array of proinflammatory 
mediators, which could act directly on surrounding cells to pro-
mote inflammation in the synovial joint.
In summary, our findings reveal that synovial Tc17 cells from 
the PsA joint bear hallmarks of Trm cells, and express high lev-
els of CXCR6, which may enhance retention of these cells in the 
inflamed joint. Our analysis of the transcriptional profile and TCR 
repertoire of these cells highlights several commonalities between 
Tc17 and Tc1 cells in the PsA joint. Combined with the observed 
polyfunctional proinflammatory mediator production, we hypoth-
esize that Tc17 cells exert heterogenous effector responses that 
contribute to the initiation and persistence of PsA.
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